• Gilead completed its previously announced acquisition of Ouro Medicines to expand its inflammation pipeline.
• The deal adds gamgertamig (OM336), a BCMAxCD3 T-cell engager in Phase 2 for antibody-driven autoimmune diseases; registrational studies expected in 2027.
• Gilead paid USD 1.68 billion upfront, with up to USD 500 million in contingent milestones; Lakefront Biotherapeutics shares up to USD 100 million.
• Lakefront takes over ongoing and future Phase 1/2 studies; Gilead leads registrational and later-stage trials, retaining global commercialization rights outside Keymed territories.
• Lakefront to receive 20%-23% tiered royalties on net sales; it also licensed three preclinical Ouro-origin programs with Gilead opt-in at USD 75 million each.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakefront Biotherapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606041615OMX_____EUPR__NL_GNW1001185945_nl) on June 04, 2026, and is solely responsible for the information contained therein.